Talley NJ Spiegel BM Foxx Orenstein AE Schiller L Quigley EM Moayyedi P Effect

Talley nj spiegel bm foxx orenstein ae schiller l

This preview shows page 64 - 67 out of 67 pages.

, Talley NJ, Spiegel BM, Foxx-Orenstein AE, Schiller L, Quigley EM, Moayyedi P. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ 2008; 337 : a2313 [PMID: 19008265 DOI: 10.1136/bmj.a2313] 253 Drossman DA , Chey WD, Johanson JF, Fass R, Scott C, Panas R, Ueno R. Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome--results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther 2009; 29 : 329-341 [PMID: 19006537 DOI: 10.1111/j.1365- 2036.2008.03881.x] 254 Ford AC , Brandt LJ, Young C, Chey WD, Foxx-Orenstein AE, Moayyedi P. Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol 2009; 104 : 1831-143; quiz 1844 [PMID: 19471254 DOI: 10.1038/ajg.2009.223]
Image of page 64
255 Andresen V , Montori VM, Keller J, West CP, Layer P, Camilleri M. Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials. Clin Gastroenterol Hepatol 2008; 6 : 545-555 [PMID: 18242143 DOI: 10.1016/j.cgh.2007.12.015] 256 Tack J , van Outryve M, Beyens G, Kerstens R, Vandeplassche L. Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives. Gut 2009; 58 : 357-365 [PMID: 18987031 DOI: 10.1136/gut.2008.162404] 257 Tack J , Talley NJ. Functional dyspepsia--symptoms, definitions and validity of the Rome III criteria. Nat Rev Gastroenterol Hepatol 2013; 10 : 134-141 [PMID: 23399526 DOI: 10.1038/nrgastro.2013.14] 258 Quigley EM , Vandeplassche L, Kerstens R, Ausma J. Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation--a 12- week, randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther 2009; 29 : 315-328 [PMID: 19035970 DOI: 10.1111/j.1365-2036.2008.03884.x] 259 Jones BW , Moore DJ, Robinson SM, Song F. A systematic review of tegaserod for the treatment of irritable bowel syndrome. J Clin Pharm Ther 2002; 27 : 343-352 [PMID: 12383135] 260 Rao S , Lembo AJ, Shiff SJ, Lavins BJ, Currie MG, Jia XD, Shi K, MacDougall JE, Shao JZ, Eng P, Fox SM, Schneier HA, Kurtz CB, Johnston JM. A 12-week, randomized, controlled trial with a 4- week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation.
Image of page 65
Am J Gastroenterol 2012; 107 : 1714-124; quiz p.1725 [PMID: 22986440] 261 Chey WD , Lembo AJ, Lavins BJ, Shiff SJ, Kurtz CB, Currie MG, MacDougall JE, Jia XD, Shao JZ, Fitch DA, Baird MJ, Schneier HA, Johnston JM. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo- controlled trial to evaluate efficacy and safety. Am J Gastroenterol 2012; 107 : 1702-1712 [PMID: 22986437] 262 Efskind PS , Bernklev T, Vatn MH. A double-blind placebo- controlled trial with loperamide in irritable bowel syndrome. Scand J Gastroenterol 1996; 31 : 463-468 [PMID: 8734343] 263 Lavö B , Stenstam M, Nielsen AL. Loperamide in treatment of irritable bowel syndrome--a double-blind placebo controlled study. Scand J Gastroenterol Suppl 1987; 130 : 77-80 [PMID: 3306903] 264 Zighelboim J , Talley NJ, Phillips SF, Harmsen WS, Zinsmeister AR. Visceral perception in irritable bowel syndrome. Rectal and gastric responses to distension and serotonin type 3 antagonism.
Image of page 66
Image of page 67

  • Left Quote Icon

    Student Picture

  • Left Quote Icon

    Student Picture

  • Left Quote Icon

    Student Picture